<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12167135
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     08
    </month>
    <day>
     08
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2002
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     02
    </month>
    <day>
     02
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0017-8748
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       42
      </volume>
      <issue>
       6
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Jun
       </month>
      </pubdate>
     </journalissue>
     <title>
      Headache
     </title>
     <isoabbreviation>
      Headache
     </isoabbreviation>
    </journal>
    <articletitle>
     Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.
    </articletitle>
    <pagination>
     <medlinepgn>
      470-82
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To assess the efficacy of tizanidine hydrochloride versus placebo as adjunctive prophylactic therapy for chronic daily headache (chronic migraine, migrainous headache, or tension-type headache).
     </abstracttext>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Tizanidine is an alpha2-adrenergic agonist that inhibits the release of norepinephrine at both the spinal cord and brain, with antinociceptive effects that are independent of the endogenous opioid system. Previous open-label studies have suggested the drug may be effective for treatment of chronic daily headache.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Two hundred patients completed a 4-week, single-blind, placebo baseline period, with 134 fulfilling selection criteria and then randomized to tizanidine or placebo. Ninety-two patients completed at least 8 weeks of treatment (tizanidine, n = 45; placebo, n = 47), and 85 patients completed 12 weeks of treatment (tizanidine, n = 44; placebo, n = 41). Most patients (77%) met the diagnostic criteria for migraine of the International Headache Society; 23% had either chronic migrainous headache or chronic tension-type headache. Tizanidine was slowly titrated over 4 weeks to 24 mg or the maximum dose tolerated (mean, 18 mg; SD, 6.4; median, 20.0; range, 2 to 24), divided equally over three dose intervals per day. Overall headache index ([headache days x average intensity x duration in hours]/28 days) was the primary end point.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Tizanidine was shown to be superior to placebo in reducing the overall headache index (P =.0025), as well as mean headache days per week (P =.0193), severe headache days per week (P =.0211), average headache intensity (P =.0108), peak headache intensity (P =.0020), and mean headache duration (P =.0127). The mean percentage improvement during the last 4 weeks of treatment with tizanidine versus placebo was 54% versus 19% for the headache index (P =.0144), 55% versus 21% for severe headache days (P =.0331), 35% versus 19% for headache duration (P =.0142), 35% versus 20% for peak headache intensity (P =.0106), 33% versus 20% for average headache intensity (P =.0281), and 30% versus 22% for total headache days (P =.0593). Patients receiving tizanidine also scored higher ratings of overall headache improvement on a visual analog scale (P =.0069). There was no statistically significant difference in outcome for patients with chronic migraine versus those with only migrainous or tension-type headache. Adverse effects reported by more than 10% of the patients included somnolence (47%), dizziness (24%), dry mouth (23%), and asthenia (19%). Dropouts due to adverse events did not differ significantly between tizanidine and placebo.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      The results support tizanidine as an effective prophylactic adjunct for chronic daily headache, including migraine, migrainous headache, and tension-type headache. These results also suggest the possible importance of an alpha2-adrenergic mechanism underlying the pathophysiology of this spectrum of headache disorders.
     </abstracttext>
    </abstract>
    <affiliation>
     Michigan Head-Pain and Neurological Institute, Ann Arbor 48104, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Saper
      </lastname>
      <forename>
       Joel R
      </forename>
      <initials>
       JR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lake
      </lastname>
      <forename>
       Alvin E
      </forename>
      <initials>
       AE
      </initials>
      <suffix>
       3rd
      </suffix>
     </author>
     <author validyn="Y">
      <lastname>
       Cantrell
      </lastname>
      <forename>
       Deborah T
      </forename>
      <initials>
       DT
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Winner
      </lastname>
      <forename>
       Paul K
      </forename>
      <initials>
       PK
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       White
      </lastname>
      <forename>
       Jeffery R
      </forename>
      <initials>
       JR
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Headache
    </medlineta>
    <nlmuniqueid>
     2985091R
    </nlmuniqueid>
    <issnlinking>
     0017-8748
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Adrenergic alpha-Agonists
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      4205-90-7
     </registrynumber>
     <nameofsubstance>
      Clonidine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      51322-75-9
     </registrynumber>
     <nameofsubstance>
      tizanidine
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Headache. 2003 Mar;43(3):296; author reply 296-7
     </refsource>
     <pmid version="1">
      12603653
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adrenergic alpha-Agonists
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Chronic Disease
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Clonidine
     </descriptorname>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Headache Disorders
     </descriptorname>
     <qualifiername majortopicyn="N">
      classification
     </qualifiername>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      8
     </month>
     <day>
      9
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2002
     </year>
     <month>
      11
     </month>
     <day>
      26
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      8
     </month>
     <day>
      9
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12167135
    </articleid>
    <articleid idtype="pii">
     hed02122
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

